- Home
- BAFN vs APLT Comparison
BAFN vs APLT Comparison
Compare BAFN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- APLT
- Stock Information
- Founded
- BAFN 1999
- APLT 2016
- Country
- BAFN United States
- APLT United States
- Employees
- BAFN N/A
- APLT N/A
- Industry
- BAFN Savings Institutions
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- BAFN Finance
- APLT Health Care
- Exchange
- BAFN Nasdaq
- APLT Nasdaq
- Market Cap
- BAFN 63.2M
- APLT 69.0M
- IPO Year
- BAFN N/A
- APLT 2019
- Fundamental
- Price
- BAFN $8.78
- APLT $0.51
- Analyst Decision
- BAFN
- APLT Buy
- Analyst Count
- BAFN 0
- APLT 6
- Target Price
- BAFN N/A
- APLT $6.10
- AVG Volume (30 Days)
- BAFN 24.3K
- APLT 826.0K
- Earning Date
- BAFN 10-23-2025
- APLT 08-13-2025
- Dividend Yield
- BAFN 3.74%
- APLT N/A
- EPS Growth
- BAFN 100.65
- APLT N/A
- EPS
- BAFN 1.89
- APLT N/A
- Revenue
- BAFN $78,211,000.00
- APLT $121,000.00
- Revenue This Year
- BAFN N/A
- APLT N/A
- Revenue Next Year
- BAFN N/A
- APLT $5,931.24
- P/E Ratio
- BAFN $4.60
- APLT N/A
- Revenue Growth
- BAFN 0.67
- APLT N/A
- 52 Week Low
- BAFN $6.40
- APLT $0.30
- 52 Week High
- BAFN $19.75
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- BAFN 38.58
- APLT 56.97
- Support Level
- BAFN $8.36
- APLT $0.48
- Resistance Level
- BAFN $10.16
- APLT $0.53
- Average True Range (ATR)
- BAFN 0.85
- APLT 0.04
- MACD
- BAFN 0.17
- APLT -0.00
- Stochastic Oscillator
- BAFN 58.19
- APLT 80.00
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.